Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
CHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.64
Previous CloseN/A
Volume565.36K
Average Volume (3M)1.91M
Market Cap
$128.64M
Enterprise Value$321.61M
Total Cash (Recent Filing)$72.36M
Total Debt (Recent Filing)$103.09M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
May 08, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding115,890,180
10 Day Avg. Volume1,281,727
30 Day Avg. Volume1,908,859
Standard Deviation0.19
R-Squared0.05
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.41
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda-2.96
Forecast
1Y Price Target
$7.00Price Target Upside530.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Coherus Biosciences News
PremiumCompany Announcements
Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook
PremiumCompany Announcements
Coherus Biosciences Announces Board Member Resignation
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCoherus scored a big win with its announced divestiture of the Udenyca franchise for ~$483.4M upfront cash payment, giving the company the ability to largely eliminate debt from its balance sheet which has been the key overhang on shares.
Product EfficacyThe company reported positive final data from a Phase 2 study in patients with metastatic hepatocellular carcinoma, showcasing the efficacy of their triplet therapy.
Bears Say
Supply Chain DisruptionCapacity constraints at its contract manufacturing organization (CMO) will result in a disruption of Udenyca supply.
---
Ownership Overview
1.22% Insiders
15.46% Mutual Funds
17.84% Other Institutional Investors
55.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.66 and its highest was $2.64 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $128.64M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is May 08, 2025 which is in 66 days.
How were Coherus Biosciences’s earnings last quarter?
Currently, no data Available
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 115,890,180 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
---
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (530.63% Upside)
$7.00 (530.63% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.96%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
-13.50%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth for UDENYCA and LOQTORZI, improved financial performance, and promising pipeline advancements. However, challenges included a supply interruption affecting UDENYCA and a net loss, though financial losses were reduced compared to the previous year.Read More>---
CHRS Stock 12 Month Forecast
Average Price Target
$7.00
▲(530.63% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Heron Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
3/25 ratings generated profit
1 Year Average Return
-32.38%
reiterated a buy rating last month
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 12.00% of your transactions generating a profit, with an average return of -32.38% per trade.
---